Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials

AIMS: To assess the effect of baseline body mass index (BMI) and the occurrence of nausea and/or vomiting on weight loss induced by semalgutide, a once‐weekly glucagon‐like peptide 1 analogue for the treatment of type 2 diabetes. Semaglutide demonstrated superior reductions in HbA1c and superior wei...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahrén, Bo, Atkin, Stephen L., Charpentier, Guillaume, Warren, Mark L., Wilding, John P. H., Birch, Sune, Holst, Anders Gaarsdal, Leiter, Lawrence A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099440/
https://www.ncbi.nlm.nih.gov/pubmed/29766634
http://dx.doi.org/10.1111/dom.13353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099440/
https://www.ncbi.nlm.nih.gov/pubmed/29766634
http://dx.doi.org/10.1111/dom.13353

Ejemplares similares